Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a novel multifunctional modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration. In the Phase 2 study, the safety and efficacy of OCU410 in patients with GA secondary to dAMD will be assessed. Fifty-one patients were randomized 1:1:1 into either of two treatment groups or a control group. In the treatment groups, subjects received a single subretinal 200-microL administration of 5 x 1010 vector genomes/mL or 1.5 x 1011 vg/mL, while the control group remained untreated. The ArMaDa clinical trial for OCU410 is being performed at 14 retinal surgery centers across the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Largest borrow rate increases among liquid names
- Ocugen’s OCU400 granted positive opinion by EMA in retinitis pigmentosa
- Ocugen files to sell 57.54M shares of common stock for holders
- Ocugen announces IND in effect after FDA review
- Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME